Burzynski Research Institute, Inc. (BZYR)
USD 0.04
(0.0%)
USD 0.04
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | - USD | 100.0% |
| 2023 | -916.29 Thousand USD | 6.18% |
| 2022 | -976.65 Thousand USD | 24.97% |
| 2021 | -1.3 Million USD | 20.38% |
| 2020 | -1.63 Million USD | 0.17% |
| 2019 | - USD | -1.53% |
| 2018 | -1.61 Million USD | -7.25% |
| 2017 | -1.5 Million USD | 24.96% |
| 2016 | -2 Million USD | 30.68% |
| 2015 | -2.89 Million USD | 32.3% |
| 2014 | -4.27 Million USD | 34.28% |
| 2013 | -6.49 Million USD | 9.2% |
| 2012 | -7.15 Million USD | -42.27% |
| 2011 | -5.03 Million USD | -4.16% |
| 2010 | -4.82 Million USD | 5.8% |
| 2009 | -5.12 Million USD | -13.43% |
| 2008 | -4.52 Million USD | -5.09% |
| 2007 | -4.3 Million USD | 8.56% |
| 2006 | -4.59 Million USD | 5.16% |
| 2005 | -4.96 Million USD | -13.47% |
| 2004 | - USD | 0.71% |
| 2003 | - USD | 14.37% |
| 2002 | -5.13 Million USD | -13.73% |
| 2001 | -4.52 Million USD | -6.8% |
| 2000 | -4.23 Million USD | 12.47% |
| 1999 | -4.83 Million USD | 29.83% |
| 1998 | -6.89 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - USD | -45.74% |
| 2024 Q4 | -362.9 Thousand USD | 16.19% |
| 2024 Q3 | -433.01 Thousand USD | -71.76% |
| 2024 Q2 | -252.1 Thousand USD | 12.28% |
| 2024 Q1 | -287.4 Thousand USD | -33.06% |
| 2023 Q2 | -215.91 Thousand USD | 6.83% |
| 2023 FY | - USD | 6.18% |
| 2023 Q4 | -215.99 Thousand USD | 14.5% |
| 2023 Q3 | -252.63 Thousand USD | -17.01% |
| 2023 Q1 | -231.73 Thousand USD | -35.61% |
| 2022 Q3 | -264.77 Thousand USD | -17.83% |
| 2022 Q1 | -316.28 Thousand USD | -26.04% |
| 2022 FY | - USD | 24.97% |
| 2022 Q4 | -170.87 Thousand USD | 35.46% |
| 2022 Q2 | -224.71 Thousand USD | 28.95% |
| 2021 Q3 | -264.32 Thousand USD | 19.55% |
| 2021 Q1 | -457.97 Thousand USD | -60.83% |
| 2021 Q4 | -250.93 Thousand USD | 5.07% |
| 2021 FY | - USD | 20.38% |
| 2021 Q2 | -328.54 Thousand USD | 28.26% |
| 2020 Q1 | -468.31 Thousand USD | -38.21% |
| 2020 Q4 | -284.75 Thousand USD | 39.63% |
| 2020 FY | - USD | 0.17% |
| 2020 Q2 | -410.22 Thousand USD | 12.4% |
| 2020 Q3 | -471.69 Thousand USD | -14.99% |
| 2019 Q4 | -338.83 Thousand USD | 22.93% |
| 2019 Q3 | -439.63 Thousand USD | 2.23% |
| 2019 FY | - USD | -1.53% |
| 2019 Q1 | -409.57 Thousand USD | -26.41% |
| 2019 Q2 | -449.67 Thousand USD | -9.79% |
| 2018 Q2 | -425.74 Thousand USD | 7.89% |
| 2018 FY | - USD | -7.25% |
| 2018 Q1 | -462.21 Thousand USD | -32.2% |
| 2018 Q3 | -401.12 Thousand USD | 5.78% |
| 2018 Q4 | -324.01 Thousand USD | 19.22% |
| 2017 FY | - USD | 24.96% |
| 2017 Q1 | -369.78 Thousand USD | 9.79% |
| 2017 Q3 | -382.96 Thousand USD | 4.65% |
| 2017 Q4 | -349.63 Thousand USD | 8.7% |
| 2017 Q2 | -401.64 Thousand USD | -8.62% |
| 2016 Q3 | -460.02 Thousand USD | 9.82% |
| 2016 Q1 | -624.35 Thousand USD | -1.24% |
| 2016 Q4 | -409.91 Thousand USD | 10.89% |
| 2016 FY | - USD | 30.68% |
| 2016 Q2 | -510.13 Thousand USD | 18.29% |
| 2015 FY | - USD | 32.3% |
| 2015 Q1 | -840.71 Thousand USD | -1.88% |
| 2015 Q4 | -616.71 Thousand USD | 12.84% |
| 2015 Q3 | -707.54 Thousand USD | 2.61% |
| 2015 Q2 | -726.51 Thousand USD | 13.58% |
| 2014 Q4 | -825.19 Thousand USD | 16.03% |
| 2014 Q2 | -1.1 Million USD | 18.46% |
| 2014 Q3 | -982.69 Thousand USD | 11.18% |
| 2014 FY | - USD | 34.28% |
| 2014 Q1 | -1.35 Million USD | 9.24% |
| 2013 Q4 | -1.49 Million USD | 2.26% |
| 2013 Q1 | -1.68 Million USD | 17.3% |
| 2013 Q2 | -1.79 Million USD | -6.78% |
| 2013 FY | - USD | 9.2% |
| 2013 Q3 | -1.52 Million USD | 14.74% |
| 2012 Q2 | -1.78 Million USD | -18.93% |
| 2012 FY | - USD | -42.27% |
| 2012 Q3 | -1.83 Million USD | -3.08% |
| 2012 Q4 | -2.03 Million USD | -10.42% |
| 2012 Q1 | -1.5 Million USD | -20.88% |
| 2011 Q4 | -1.24 Million USD | -2.65% |
| 2011 Q3 | -1.2 Million USD | -0.43% |
| 2011 Q1 | -1.37 Million USD | -5.14% |
| 2011 Q2 | -1.2 Million USD | 12.42% |
| 2011 FY | - USD | -4.16% |
| 2010 Q4 | -1.3 Million USD | -8.21% |
| 2010 Q2 | -1.19 Million USD | -6.78% |
| 2010 FY | - USD | 5.8% |
| 2010 Q1 | -1.11 Million USD | 7.97% |
| 2010 Q3 | -1.2 Million USD | -1.19% |
| 2009 Q3 | -1.34 Million USD | -4.03% |
| 2009 FY | - USD | -13.43% |
| 2009 Q1 | -1.28 Million USD | -0.27% |
| 2009 Q2 | -1.28 Million USD | -0.64% |
| 2009 Q4 | -1.21 Million USD | 9.43% |
| 2008 FY | - USD | -5.09% |
| 2008 Q4 | -1.27 Million USD | -24.23% |
| 2008 Q3 | -1.02 Million USD | 10.73% |
| 2008 Q1 | -1.06 Million USD | -1.98% |
| 2008 Q2 | -1.15 Million USD | -8.67% |
| 2007 Q1 | -1.15 Million USD | -8.11% |
| 2007 Q4 | -1.03 Million USD | -8.49% |
| 2007 Q3 | -958.59 Thousand USD | 16.34% |
| 2007 Q2 | -1.14 Million USD | 0.96% |
| 2007 FY | - USD | 8.56% |
| 2006 Q1 | -1.18 Million USD | 8.94% |
| 2006 Q2 | -1.3 Million USD | -10.53% |
| 2006 Q3 | -1.14 Million USD | 12.31% |
| 2006 Q4 | -1.07 Million USD | 6.59% |
| 2006 FY | - USD | 5.16% |
| 2005 Q2 | -1.21 Million USD | 6.26% |
| 2005 Q4 | -1.29 Million USD | -11.9% |
| 2005 Q3 | -1.15 Million USD | 4.2% |
| 2005 Q1 | -1.29 Million USD | -0.01% |
| 2005 FY | - USD | -13.47% |
| 2004 FY | - USD | 0.71% |
| 2004 Q1 | -1.06 Million USD | 12.75% |
| 2004 Q2 | -1.13 Million USD | -7.09% |
| 2004 Q3 | -883.66 Thousand USD | 22.18% |
| 2004 Q4 | -1.29 Million USD | -46.15% |
| 2003 Q3 | -1.1 Million USD | -9.37% |
| 2003 FY | - USD | 14.37% |
| 2003 Q1 | -1.07 Million USD | 11.77% |
| 2003 Q2 | -1.01 Million USD | 5.81% |
| 2003 Q4 | -1.21 Million USD | -9.98% |
| 2002 FY | - USD | -13.73% |
| 2002 Q4 | -1.21 Million USD | -0.51% |
| 2002 Q1 | -1.4 Million USD | -29.19% |
| 2002 Q2 | -1.3 Million USD | 6.89% |
| 2002 Q3 | -1.2 Million USD | 7.47% |
| 2001 Q4 | -1.08 Million USD | 9.02% |
| 2001 Q2 | -1.17 Million USD | -10.34% |
| 2001 Q1 | -1.06 Million USD | -6.31% |
| 2001 FY | - USD | -6.8% |
| 2001 Q3 | -1.19 Million USD | -1.63% |
| 2000 Q4 | -1 Million USD | -7.36% |
| 2000 FY | - USD | 12.47% |
| 2000 Q1 | -1.26 Million USD | 0.0% |
| 2000 Q2 | -1.03 Million USD | 17.69% |
| 2000 Q3 | -933.11 Thousand USD | 10.07% |
| 1999 FY | - USD | 29.83% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 100.0% |
| SQZ Biotechnologies Company | -64.14 Million USD | 100.0% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.0% |
| Mesoblast Limited | -62.38 Million USD | 100.0% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 100.0% |
| Genus plc | 73.7 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 100.0% |
| Marizyme, Inc. | -34.28 Million USD | 100.0% |
| ContraFect Corporation | -64.99 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 100.0% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 100.0% |
| Accustem Sciences Inc. | -3.74 Million USD | 100.0% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 100.0% |
| EV Biologics, Inc. | -1.26 Million USD | 100.0% |
| Q BioMed Inc. | -617.62 Thousand USD | 100.0% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 100.0% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 100.0% |
| Biomind Labs Inc. | -1.03 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Pharming Group N.V. | 9.87 Million USD | 100.0% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 100.0% |
| Skye Bioscience, Inc. | -13.54 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 100.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 100.0% |
| IMV Inc. | -35.52 Million USD | 100.0% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 100.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 100.0% |
| GB Sciences, Inc. | -1.41 Million USD | 100.0% |
| Alpha Cognition Inc. | -9.7 Million USD | 100.0% |
| HST Global, Inc. | -5303.00 USD | 100.0% |
| CSL Limited | 4.78 Billion USD | 100.0% |
| Halberd Corporation | -74.27 Thousand USD | 100.0% |
| Enzolytics Inc. | -2.12 Million USD | 100.0% |
| Resverlogix Corp. | -11.74 Million USD | 100.0% |
| Affymax, Inc. | -14.29 Million USD | 100.0% |
| SYBLEU INC | -141.57 Thousand USD | 100.0% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 100.0% |
| argenx SE | -216.02 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 100.0% |
| AVAX Technologies, Inc. | -6.11 Million USD | 100.0% |
| Zenith Capital Corp. | -8.6 Million USD | 100.0% |
| Genscript Biotech Corporation | -248.71 Million USD | 100.0% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 100.0% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Helix BioMedix, Inc. | -1.04 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 100.0% |
| BioStem Technologies, Inc. | -7.55 Million USD | 100.0% |
| ONE Bio Corp. | 13.61 Million USD | 100.0% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 100.0% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 100.0% |
| Agentix Corp. | -1.37 Million USD | 100.0% |
| LadRx Corporation | 412.28 Thousand USD | 100.0% |
| Cell Source, Inc. | -4.27 Million USD | 100.0% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 1.46 Million USD | 100.0% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 100.0% |
| NovAccess Global Inc. | -1.03 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 100.0% |
| Itoco Inc. | -1.86 Million USD | 100.0% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 100.0% |
| Kadimastem Ltd | -2.62 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 100.0% |
| CytoDyn Inc. | -18.02 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 100.0% |
| Mobile Lads Corp. | -2.24 Million USD | 100.0% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 100.0% |
| Qrons Inc. | -40.08 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 100.0% |
| Rebus Holdings, Inc. | -951 Thousand USD | 100.0% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 100.0% |
| International Stem Cell Corporation | 202 Thousand USD | 100.0% |
| Bioxytran, Inc. | -3.82 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | -2.46 Million USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | -35.86 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | - USD | NaN% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | -45 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 100.0% |
| Neutra Corp. | -181.24 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 100.0% |
| PureTech Health plc | -11.62 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 100.0% |
| IXICO plc | -707 Thousand USD | 100.0% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 100.0% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 100.0% |
| CSL Limited | 4.73 Billion USD | 100.0% |
| Cellectis S.A. | -92.63 Million USD | 100.0% |